Informations sur le produit
- Atosiban [USAN:INN]
- Rwj 22164
- 1-(3-Mercaptopropionic acid)-2-(3-(p-ethoxyphenyl)-D-alanine)-4-L-threonine-8-L-ornithineoxytocin
- 1-Deamino-2D-tyr-(OEt)-4-thr-8-orn-oxytocin
- Atosibanum
- Atosibanum [INN-Latin]
- Orf 22164
- Tractocile
- Unii-081D12Si0Z
- Oxytocin, 1-(3-mercaptopropanoic acid)-2-(O-ethyl-D-tyrosine)-4-L-threonine-8-L-ornithine-
- Voir d'autres synonymes
- 1-({(4R,7S,13S,16R)-7-(2-amino-2-oxoethyl)-13-[(2S)-butan-2-yl]-16-(4-ethoxybenzyl)-10-[(1R)-1-hydroxyethyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosan-4-yl}carbonyl)-L-prolyl-L-ornithylglycinamide
Atosiban is a drug used to prevent preterm birth in pregnant women. The drug binds to and blocks the action of oxytocin, a hormone that stimulates uterine contractions, preventing preterm birth. Atosiban prevents uterine contractions by binding to oxytocin receptors and blocking them from binding with oxytocin. Atosiban also has anti-inflammatory properties and can be used as an analgesic.
Atosiban is administered orally as a prodrug that is converted into the active form in the intestines. This conversion is dependent on the presence of an intestinal disulfide bond reductase enzyme, which converts atosiban to its active form by reducing the disulfide bond between two cysteine residues found within the molecule.
Atosiban has been shown to have few side effects in women, but may cause nausea or vomiting after administration.
